II. Amendments To The Claims

1. - 18. (cancelled)

19. (currently amended) A method for the treatment of male erectile dysfunction which comprises administering **to a male in need thereof** a pharmacologically effective amount of a composition comprising ~~**one or more of the following pharmaceutical agents selected from the group consisting of**~~ an α-adrenergic blocker~~**, a phosphodiesterase inhibitor,**~~ and a prostaglandin in a buffer.

20. (original) The method of claim 19 wherein the α-adrenergic blocker is phentolamine mesylate, or any pharmaceutically acceptable salt thereof.

21. (cancelled)

22. (original) The method of claim 19 wherein the prostaglandin is alprostadil.

23. (original) The method of claim 19 wherein the buffer comprises L-arginine and, optionally, a pharmaceutically acceptable excipient or carrier.

24. (original) The method of claim 23 wherein the buffer comprises glycine having a pH range of from about 3 to about 5.

25. (original) The method of claim 19 wherein the buffer comprises a mixture of arginine and glycine having a pH range of from about 3 to about 5.

26. (original) The method of claim 19 wherein the buffer comprises glycine and L-arginine in a weight ratio of about 1:20.

27. (original) The method of claim 25 wherein the buffer further comprises benzyl alcohol and mannitol and has a pH range of from about 3 to about 5.

28. (currently amended) The method of claim 19 wherein the weight ratio of **phentolamine mesylate: alprostadil** ~~**phentolamine mesylate: papaverine hydrochloride: alprostadil**~~ is about **0.5:0.005** ~~**0.5:7.5:0.005**~~ to about **5: 0.20** ~~**5:30:0.20**~~.

29. (currently amended) The method of claim 19 wherein the weight ratio of **phentolamine mesylate: alprostadil** ~~**phentolamine mesylate: papaverine hydrochloride: alprostadil**~~ is about **1:0.01** ~~**1:30:0.01**~~.

30. (currently amended) The method of claim 19 wherein the dosage of phentolamine mesylate~~, papaverine hydrochloride,~~ and alprostadil are in the range of about 0-40 μg/ml alprostadil~~, about 0-50 mg/ml papaverine,~~ and about 0-10 mg/ml phentolamine.

31. (currently amended) The method of claim 19 wherein the dosage of phentolamine mesylate~~, papaverine hydrochloride,~~ and alprostadil are in the range of about 1.25-5 mg/ml phentolamine~~, about 7.5-30 mg/ml papaverine,~~ and about 5-20 μg/ml alprostadil.

32. (currently amended) The method of claim 19 wherein the dosage of phentolamine mesylate~~, papaverine hydrochloride,~~ and alprostadil are about 1 mg/ml phentolamine~~, about 30 mg/ml papaverine,~~ and about 0.01 mg/ml alprostadil.

33. (currently amended) The method of claim 30, 31, or 32 wherein the vasoactive agents are present in a total volume of 0.5 **ml** ~~μl~~.

34. (original) The method of claim 19 wherein the dosage of alprostadil is about 5 μg/ml in a total volume of 0.5 ml.

35. (original) The method of claim 19 wherein the dosage of phentolamine is about 1.25 mg/ml in a total volume of 0.5 ml.

36. (original) The method of claim 19 wherein the pH range of the buffer is from about 3 to about 7.

37. - 46. (cancelled)